Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)
Crinetics Pharmaceuticals' (CRNX) quarterly Preferred Stock Liabilities came in at $93.0 million in Q2 2018, up 213.05% quarter-over-quarter from $29.7 million in Q4 2017.
Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Crinetics Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $93.0 million for Q2 2018.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $93.0 million in Q2 2018; TTM through Jun 2018 was $93.0 million, a N/A change from a year earlier, with the FY2017 full-year figure at $29.7 million, up 67.42% from the prior year.
- Preferred Stock Liabilities improved to $93.0 million in Q2 2018 per CRNX's latest filing, from $29.7 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $93.0 million in Q2 2018 and bottomed at $29.7 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Crinetics Pharmaceuticals | 8.71 Bn | 8.71 Bn | 10.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 92.98 Mn |
| Dec 31, 2017 | 29.70 Mn |